Larimar Therapeutics
LRMR
107 hedge funds and large institutions have $473M invested in Larimar Therapeutics in 2024 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 41 increasing their positions, 33 reducing their positions, and 21 closing their positions.
905% more call options, than puts
Call options by funds: $3.29M | Put options by funds: $328K
24% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 33
14% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 21
3% more funds holding
Funds holding: 104 → 107 (+3)
2.68% more ownership
Funds ownership: 99.71% → 102.39% (+2.7%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
2% less capital invested
Capital invested by funds: $483M → $473M (-$9.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$7.01M |
| 2 |
BlackRock
New York
|
+$6.09M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.02M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$3.29M |
| 5 |
Janus Henderson Group
London,
|
+$2.73M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$8.88M |
| 2 |
RI
RTW Investments
New York
|
-$4.93M |
| 3 |
Renaissance Technologies
New York
|
-$1.72M |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$1.6M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.32M |
LRMR Hedge Fund Activity: Q2 2024 in Review
107 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q2 2024, worth a combined $473M — down 1.9% from $483M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new LRMR positions and 21 closed out — a net gain of 3 holders — while 41 added to existing stakes and 33 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $7.01M. The largest seller was Citadel Advisors, cutting an estimated $8.88M.
- 107 institutional investors held Larimar Therapeutics (LRMR) as of Q2 2024, up from 104 in Q1 2024.
- Funds reported $473M of Larimar Therapeutics stock for Q2 2024, down 1.9% quarter-over-quarter.
- 24 funds opened new Larimar Therapeutics positions in Q2 2024 and 21 closed out, a net change of +3 holders.
- The largest Larimar Therapeutics buyer in Q2 2024 was Goldman Sachs, an estimated $7.01M added.
- The largest Larimar Therapeutics seller in Q2 2024 was Citadel Advisors, an estimated $8.88M sold.
Based on aggregated 13F filings for Q2 2024.